OX40 competitor failures create vacuum for Nectar
The guest argued that the efficacy collapse and safety issues (Kaposi's sarcoma) of competing OX40-class drugs from Amgen and Sanofi have created a massive market-share vacuum for Nectar's ResPeg.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.